AzurRx BioPharma to Present at the Emerging Growth

AzurRx BioPharma to Present at the Emerging Growth

News Highlights

DELRAY BEACH, Fla., May 11, 2021 (News) — AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that the Company will make a virtual presentation at the Emerging Growth Conference taking place on Wednesday, May 12th, 2021.

During their live virtual presentation at 10:30 a.m. EDT, members of AzurRx’s management team will provide an overview of AzurRx’s business and clinical development programs and discuss anticipated 2021 and early 2022 milestones.

Details of the presentation are as follows:

If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available on EmergingGrowth.com and we will also release a link to that after the event.

About the Emerging Growth Conference The Emerging Growth conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community from the convenience of their office, in a time efficient manner.

The Conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long term growth. Its audience includes potentially tens of thousands of Individual and Institutional investors, as well as Investment advisors and analysts. All sessions will be conducted through video webcasts and will take place in the Eastern time zone.

About AzurRx BioPharma, Inc.AzurRx BioPharma, Inc. (NASDAQ: AZRX) is a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company has a pipeline of three gut-restricted GI assets. The lead therapeutic candidate is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis, currently in two Phase 2 clinical trials. AzurRx is launching two clinical programs using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor, FW-420, for grade 1 Immune Checkpoint Inhibitor Colitis and diarrhea in oncology patients and FW-1022, for COVID-19 gastrointestinal infections. The Company is headquartered in Delray Beach, Florida with clinical operations in Hayward, California. For more information, visit www.azurrx.com.

Forward-Looking StatementThis press release may contain certain statements relating to future results which are forward-looking statements. It is possible that the Company’s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements, depending on factors including whether results obtained in preclinical and nonclinical studies and clinical trials will be indicative of results obtained in future clinical trials; whether preliminary or interim results from a clinical trial will be indicative of the final results of the trial; and the impact of the coronavirus (COVID-19) pandemic on the Company’s operations and current and planned clinical trials, including potential delays in clinical trial recruitment and participation. Additional information concerning the Company and its business, including a discussion of factors that could materially affect the Company’s financial results are contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 under the heading “Risk Factors,” as well as the Company’s subsequent filings with the Securities and Exchange Commission. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

For more information:AzurRx BioPharma, Inc.1615 South Congress AvenueSuite 103Delray Beach, Florida 33445Phone: (646) 699-7855info@azurrx.com

Media contact:Tiberend Strategic Advisors, Inc.Johanna Bennett/Ingrid Mezo(212) 375-2665/(646) 604-5150jbennett@tiberend.com/imezo@tiberend.com

 

  • Check the latest Health news updates and information.
  • Please share this news AzurRx BioPharma to Present at the Emerging Growth with your friends and family to support us your one share helps us a lot.
Disclaimer: If you need to edit or update this news from compsmag then kindly contact us Learn more

For Latest News Follow us on Google News


Latest Headlines
  • Show all
  • Trending News
  • Popular By week
Goldman expands into encryption business with plans for Ether options

Goldman expands into encryption business with plans for Ether options

In May, Goldman led the $15 million investment into Coin Metrics, a cryptocurrency and blockchain data provider to institutional clients, and McDermott joined ...
This Xbox controller from Turtle Beach comes with its own sound mixer

This Xbox controller from Turtle Beach comes with its own sound mixer

The Turtle Beach Recon Controller is a wired gamepad that will release sometime this summer and retail for $60, the same price that Microsoft’s official ...
Why Did the Xbox Series X Game Miss E3? Everwild Report explains why the Xbox Series X game missed E3

Why Did the Xbox Series X Game Miss E3? Everwild Report explains why the Xbox Series X game missed E3

In a statement to VGC, Rare’s Louise O’Connor confirmed that Mayles has joined the team, but it should be noted that she did not address the rumored release ...
The company fire along I-35 on the Northeast Side started in a palm tree, says SAFD

The company fire along I-35 on the Northeast Side started in a palm tree, says SAFD

Read also: No one was injured in the fire, which is under investigation. Copyright 2021 by KSAT – All rights reserved. According to the San Antonio Fire ...
This $2,700 robot dog will carry a single bottle of water for you

Biden returns $26 million in cash from the border wall to the navy shipyard

Source www.wtvr.com The facility builds and repairs U.S. Navy ships. The Norfolk Naval Shipyard in Portsmouth will use the $26 million to address numerous ...
Stranger at Home in Central City Strikes Homeowner, Fires Gun and Steals Money from Safe, Says NOPD |  Crime / Police

Stranger at Home in Central City Strikes Homeowner, Fires Gun and Steals Money from Safe, Says NOPD | Crime / Police

Purchases made via links on our site may earn us an affiliate commission A woman was working in a store in the 600 block of Decatur Street at 10:51 p.m. Sunday ...
New material has amazing thermal properties

New material has amazing thermal properties

One example of where material can be useful is aerospace design, where components are exposed to extreme cold in space and extreme heat when launched or ...
At the Xbox Games Show, EA unveiled a Battlefield gameplay trailer

At the Xbox Games Show, EA unveiled a Battlefield gameplay trailer

The trailer today showed gameplay of a 128-player match of conquest. The map for the trailer was set in a large cityscape surrounded by sand dunes. Besides ...
‘Prepare for cryptography,’ Tanzania’s president tells finance chiefs

‘Prepare for cryptography,’ Tanzania’s president tells finance chiefs

Usage in Africa Shortly thereafter on June 9, President Bukele submitted a bill that would recognize bitcoin as legal tender in the country. The bill then ...
Costs Continue to Fall in the Federal Health Insurance Market

Costs Continue to Fall in the Federal Health Insurance Market

Overall, premiums for returning consumers have dropped over 40 percent for returning consumers on HealthCare.gov since April 1. APTC amounts have also ...
Show next
Compsmag - Latest News from tech, business and health
Logo